Digital Look

Welcome to Digital Look++,
you are not logged in

AbbVie Inc (ABBV)

$ 248.63

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-21	56,197.00	12,989.00	648.00¢	20.9	0.2	+137%	531.00¢	3.9%
31-Dec-22	58,054.00	13,477.00	665.00¢	24.3	8.1	+3%	571.00¢	3.5%
31-Dec-23	54,318.00	6,250.00	273.00¢	56.8	n/a	-59%	599.00¢	3.9%
31-Dec-24	56,334.00	3,716.00	240.00¢	74.0	n/a	-12%	629.00¢	3.5%
31-Dec-25	61,160.00	6,597.00	237.00¢	96.4	n/a	-1%	665.00¢	2.9%

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-26	67,253.29	31,338.16	1,424.05¢	17.7	0.0	+501%	684.05¢	0.0%
31-Dec-27	72,816.05	35,617.01	1,623.84¢	15.5	1.1	+14%	717.84¢	0.0%

AbbVie to buy biotech firm Apogee Therapeutics f...	22-Jun-2026	ShareCast
First Development Resources reports encouraging ...	19-Feb-2026	ShareCast
AstraZeneca sells hypertension drug rights; End...	27-Jan-2020	ShareCast

Abbvie boss blasts US tax regime	21-Oct-2014	Telegraph
Drug company AbbVie takeover rival in £31bn bid	18-Jul-2014	Express & Star
AbbVie to announce firm bid for Shire	18-Jul-2014	Telegraph

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Forecast figures based on normalised accounts.